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The etiology of common complex diseases is multifactorial, involving both genetic,
and environmental factors. A role for mitochondrial dysfunction and mitochondrial DNA
(mtDNA) variation has been suggested in the pathogenesis of common complex traits.
The aim of this study was to investigate a potential role of mtDNA variants in the
development of obesity, diabetes, and atherosclerosis in the Polish population. Whole
mtDNA sequences from 415 Polish individuals representing three disease cohorts and
a control group were obtained using high-throughput sequencing. Two approaches for
the assessment of mtDNA variation were applied, traditional mitochondrial haplogroup
association analysis and the mutational or variant load model using the MutPred
pathogenicity prediction algorithm for amino acid substitutions in humans. We present a
possible association between mildly deleterious mtDNA variant load and atherosclerosis
that might be due to having more than one likely mildly deleterious non-synonymous
substitution. Moreover, it seems largely dependent upon a few common haplogroup
associated variants with MutPred score above 0.5.
Keywords: mtDNA variation, MutPred, variant load, common complex diseases, atherosclerosis
INTRODUCTION
The growing worldwide prevalence of obesity, diabetes and atherosclerosis, common complex
traits associated with modern lifestyle, has a high socioeconomic cost, making solving their
pathomechanisms a pressing problem. The etiology of common complex diseases is by definition
multifactorial, involving both genetic and environmental factors, as well as the interaction between
the two. A role for mitochondrial dysfunction in many common complex, metabolic, and
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degenerative diseases has been suggested and investigated
in many studies (Wallace, 2005, 2013). Supporting this,
mitochondria are central to pathways crucial for cellular
homeostasis (Wallace, 2013; Venter et al., 2018).
Mitochondrial DNA (mtDNA) is maternally inherited and
variation acquired throughout the evolution of mtDNA has
defined the emergence of distinct lineages in the human
population, called haplogroups (Chinnery and Schon, 2003;
Elson and Lightowlers, 2006). Although mtDNA is small, it
encodes 13 respiratory chain proteins and 24 RNAs necessary
for their translation, all indispensable for energy production
through the oxidative phosphorylation (Anderson et al., 1981).
Mutations of mtDNA are an important cause of inherited disease
(Gorman et al., 2016). An epidemiological study in theNorth East
of England established minimum prevalence of adult mtDNA
disease as 1 in 5,000 demonstrating that as a group they are
among the most common inherited human diseases (Gorman
et al., 2015). MtDNA mutations cause a variety of disorders that
affect tissues with high energy demands, such as Leber hereditary
optic neuropathy (LHON) and mitochondrial encephalopathy,
lactic acidosis, and stroke-like episodes (MELAS) (Gorman et al.,
2016). Mitochondrial diseases are clinically heterogeneous and
can result in a broad range of symptoms, including diabetes
mellitus and cardiomyopathy (Wallace, 2013). Interestingly,
the m.3243A>G mutation in one of the mitochondrial tRNA
Leu genes, which is associated primarily with MELAS (∼80%
of cases), can also cause another syndrome called maternally
inherited diabetes and deafness (MIDD) (Gorman et al., 2016).
However, the m.3243A>G mutation manifesting as MIDD
explains <0.5% of type 2 diabetes cases (in UK Caucasians)
(Saker et al., 1997).
Many studies have suggested that the role of mtDNA
variation in human health is not limited to inherited
mitochondrial disorders, but that mtDNA population variation
might contribute to the pathogenesis of common complex
diseases (Herrnstadt and Howell, 2004; Wallace, 2010). The
mitochondrial genome was implied to contribute to their
missing heritability (Hudson et al., 2014). Pedigree analysis
in families affected with diabetes showed that inheritance
in the maternal line was more frequently observed than in
the paternal line (Lyssenko et al., 2015), which suggests a
contribution of the mtDNA in diabetes pathogenesis. Obesity
is a well-known phenotype associated with the lifestyle of
food overconsumption and physical inactivity that might be
ameliorated or exacerbated by inherited genetic variants that
play a role in metabolic pathways. It has been speculated that
biochemical differences in mitochondrial respiratory chain
function may predispose to obesity. These differences have
been postulated to result from different efficiency of coupling of
electron transport to ATP synthesis by the respiratory chain, that
is the efficiency of converting protons from nutrients to ATP.
Tightly coupled mitochondria produce maximum amount of
ATP per calorie consumed with minimum energy dispersed as
heat (Wallace, 2005). Uncoupling of the mitochondrial oxidative
phosphorylation system was observed to prevent obesity in
mice under a high-calorie diet (Li et al., 2000). This suggests
that stronger mitochondrial coupling might be a risk factor for
obesity as fewer calories and thus less food would be required
to produce the same amount of ATP, therefore leading to fat
storage in case of excessive food intake. Obesity is also one
of the best recognized risk factors for type 2 diabetes mellitus
(T2DM). Both conditions can lead to serious cardiovascular
complications, such as atherosclerosis and myocardial infarction.
One of the notable pathomechanisms of atherosclerosis links this
cardiovascular disease with mitochondrial function. It implies
the essential role of oxidative stress and inflammatory state due
to increased levels of reactive oxygen species (ROS) and the
mitochondrial respiratory chain is considered the major site of
ROS production. Progress of inflammation in the walls of large
arteries contributes to formation and deposition of lipid plaques
and change of arterial structure eventually leading to closing
of the lumen (Matsuda and Shimomura, 2013; Venter et al.,
2018). Inflammation has also been postulated in obesity where
elevated levels of systemic oxidative stress have been reported,
and diabetes where oxidative stress induced by hyperglycemia
has been implicated in vascular complications and pancreatic
β-cell failure (Matsuda and Shimomura, 2013).
The mitochondrial genome has a high level of sequence
variation with different populations being characterized by
(region) specific patterns of polymorphisms, which define
mitochondrial haplogroups (Torroni et al., 1996; Wallace
et al., 1999; Herrnstadt et al., 2002). Mitochondrial haplogroup
association study is one of the most common approaches to
investigate the role of mtDNA variation in human complex
diseases. This hypothesis is similar to the “common-disease
common-variant” hypothesis where common genetic variants
found deep within the phylogeny are investigated. Significant
association of a disease with one mtDNA haplogroup suggests
that a common variant or variants of mtDNA associated with
the haplogroup contribute to disease development as risk or
protective factors.
Besides looking for common mtDNA variants affecting the
risk of a common complex disease or course of that disease,
a hypothesis considering the cumulative effect of multiple
mostly rare mildly deleterious variants (a “rare-variant common-
disease” hypothesis) is gaining interest (Elson et al., 2006; Pienaar
et al., 2017; Venter et al., 2017). A rare variant may be a
risk factor in isolation or combined with more rare variants
or a common polymorphism. Since natural selection removes
variants that are mildly deleterious from the population, they
are likely to be rare and more frequent in younger branches of
mtDNA phylogeny (Elson et al., 2004; Pereira et al., 2011; Soares
et al., 2013; Wei et al., 2017). Thanks to the next generation
sequencing methods that allow high throughput sequencing in
a cost-effective and time-saving manner studies that sequence
the complete mitochondrial chromosome can, and should, now
be done routinely to investigate the role of mtDNA variation in
complex traits.
One approach to using complete mtDNA sequence data is
to make an estimate of the cumulative impact of a person’s
non-synonymous mtDNA variation, which can be done using
a variety of methodologies. One such method is to use the
MutPred algorithm for the prediction of the impact of amino
acid substitutions in humans. This tool has been well-validated in
Frontiers in Genetics | www.frontiersin.org 2 January 2019 | Volume 9 | Article 702
Piotrowska-Nowak et al. Mildly Deleterious mtDNA Variants in Atherosclerosis
the mitochondrial context having been utilized in the assessment
of mtDNA variation in a number of studies (Pereira et al.,
2011, 2012; Pienaar et al., 2017; Venter et al., 2017). MtDNA
association studies based on complete mtDNA sequence data,
and investigating the role of high (>0.5) MutPred scoring
variants is considered a good approach as these variants are
predicted to affect protein function (Pienaar et al., 2017; Venter
et al., 2017).
In view of the information outlined above, we addressed
the issue of genetic predisposition to the common complex
diseases by investigating the role of mtDNA variation in obesity,
T2DM and atherosclerosis with the traditional mitochondrial
haplogroup association approach and with the mutational or
variant load model using the MutPred tool. The presented work
investigated the contribution of inherited mtDNA population
variants, somatic variation was not the object of this study.
MATERIALS AND METHODS
Sample Collection
DNA samples used in this study were collected from peripheral
blood of 415 Polish individuals, aged 27–82 years, representing
three disease cohorts and a control group. The three patient
populations consisted of 100 participants each and included
individuals with a) diagnosed T2DM (according to criteria
meeting Polish Diabetes Association recommendations) and
preferably with possible maternal inheritance; b) obesity based
on BMI index above 30 (and preferably >35) without diabetes;
and c) atherosclerosis enrolled by previous myocardial infarction
(preferably at a young age and below 50 y/o for men and 60 y/o
for women) which is most commonly caused by atherosclerosis.
The 115 control subjects were matched for ethnicity, gender, and
age to patients and recruited based on the following inclusion
criteria: (a) glycaemia within normal range (3.9–5.5 mmol/l) and
no diabetes; (b) BMI within normal range (18.5–24.99); and
(c) no history of myocardial infarction in subjects and their
parents. Case-control studies are not always capable of capturing
the continuous process of disease development, apparent in
many complex traits and particularly in atherosclerosis. Thus, in
this study one of the final clinical consequences of the disease,
myocardial infarction, served as an indicator of the degree
of disease progression instead of a disease inclusion/exclusion
criterion. Samples included in this study were collected
in two research centers: Department of Medical Genetics,
Medical University of Warsaw (T2DM) and Department of
Epidemiology, Cardiovascular Disease Prevention and Health
Promotion, Institute of Cardiology (obesity, atherosclerosis and
controls) with the latter subjects selected from the Multi-Center
National Population Health Examination Survey (WOBASZ
study) (Drygas et al., 2016).
Ethical Statements
All procedures on human genetic material and data within this
study were performed in accordance with the ethical principles of
the local Ethics Committee of the Medical University of Warsaw
(approval number KB/264/2012) and the Declaration of Helsinki.
Informed consent was obtained from all individual participants
prior to the inclusion in the study.
mtDNA Sequencing and Analysis
Whole mitochondrial genome amplification for sequencing
was performed on total DNA of each subject as one or
two overlapping fragments using the long-range PCR.
Sequences and positions of both primer sets are depicted
in Supplemental Table 1. PCR reactions were performed
according to the rapid protocol of PrimeSTAR GXL DNA
Polymerase kit (TaKaRa Bio Inc., Kusatsu, Japan) with minor
modifications: primers at a final concentration of 0.2µM
each, 0.3125U of polymerase, up to 100 ng of genomic DNA
as a template and a 25-µl volume reaction. 3-step PCR with
3 and 1.5-min extension time was used for single and two
amplicons, respectively. The annealing temperature was set to
64◦C for single PCR product, 59 and 62◦C for products A and B,
respectively. PCR products were purified using 0.6 × volume of
Agencourt AMPure XP magnetic beads (Beckman Coulter, Brea,
USA) and quantified with Qubit dsDNA High Sensitivity Assay
Kit and Qubit fluorometer (Thermo Fisher Scientific, Waltham,
USA). Indexed mtDNA libraries were processed for sequencing
using Nextera XT DNA Sample Preparation Kit and Nextera
XT Index Kit (Illumina Inc., San Diego, USA) according to
the manufacturer’s protocol. Massively parallel sequencing was
performed on the Illumina MiSeq instrument with a 301-cycle
paired-end read chemistry, MiSeq Reagent Kit v3 (Illumina Inc.,
San Diego, USA).
Base calling, demultiplexing and FASTQ file generation
were automatically performed on the MiSeq platform (Illumina
Inc., San Diego, USA). Quality control of sequencing reads,
alignment to the human mtDNA reference sequence (rCRS,
NC_012920) and variant detection were performed using CLC
Genomics Workbench software (CLC bio, Aarhus, Denmark).
Themitochondrial haplogroupwas predicted for each participant
using Mitomaster, an online mtDNA sequence analysis tool (Lott
et al., 2013), based on a full set of SNVs. A more detailed
description of the methodology used here can be found in a
paper by Piotrowska-Nowak et al. (2019). The variant population
frequency was obtained using a dataset of over 30 000 human
mtDNA sequences deposited in GenBank and available from the
MITOMAP database (Lott et al., 2013). Variants with a GenBank
frequency <0.1% were assigned as rare.
MutPred provides a prediction of the probability of
deleterious amino acid substitution based on its impact on the
evolutionary conservation, structural and functional properties
of protein (Li et al., 2009; Pereira et al., 2011; Hepp et al.,
2015). It has numerical scoring system with 0–1 value range.
Variants with a score above 0.5 are considered as potentially
deleterious to protein function (“actionable hypothesis” that the
molecular mechanism would be disrupted) and those with a
score above 0.75 as high confidence harmful changes (Li et al.,
2009; Pereira et al., 2011). MutPred scores were assigned to all
operationally homoplasmic non-synonymous substitutions of
each subject using mtDNA Server (Weissensteiner et al., 2016).
The effect of heteroplasmic mtDNA variants was not investigated
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here. MutPred mutational load of each patient’s sequence—
here referred to as “variant load” to clarify that what is being
measured is the burden of predicted mildly deleterious variants
in individuals in case and control cohorts—was calculated as
the sum of MutPred scores for all non-synonymous variants
detected in a sample, as described previously (Pienaar et al.,
2017; Venter et al., 2017). In this study only variants with high
MutPred scores, that is above the 0.5 threshold, were used for
calculations as they are more likely to be deleterious and thus
are suggested to give a clearer indication of a pathogenic load
(Pienaar et al., 2017; Venter et al., 2017).
The 415 mitochondrial sequences investigated in this study
are available at GenBank under accession numbers MH120425-
MH120839.
Statistical Analysis
The differences in the mitochondrial haplogroup distribution
between disease cohorts and the control group were investigated
by Fisher’s exact test. Post-hoc analysis of the contingency table
using the adjusted standardized residual (adj. std. res.) method
was carried out to determine the relationship. Strength of the
association for statistically significant outcome was estimated
using Phi coefficient (φ).
A one-way ANOVA followed by a Dunnett’s post-hoc test
was used to compare mean MutPred derived mildly deleterious
variant loads in diabetic, obese and atherosclerotic patients to
the control group. The frequency of rare mtDNA variants (with
GenBank frequency below 0.1%) was examined between each of
the three disease groups and controls separately using Fisher’s
exact test. The prevalence of participants having variants with
MutPred score above 0.5 or 0.7 was compared among disease
cohorts and control subjects with Fisher’s exact test. The number
of individuals having one or more high scoring variants (that
is with MutPred score above 0.5) in each phenotype cohort
was compared to the control group using Fisher’s exact test. A
Bonferroni correction of p-value for multiple testing was applied
where appropriate. The statistical analysis was performed using
IBM SPSS Statistics software (IBM Corporation, Armonk, USA).
The results were considered statistically significant when the
p-value was <0.05.
RESULTS
In the current study, mtDNA variation in common complex
diseases was analyzed using the case-control approach.
Characteristics of the studied cohorts are shown in Table 1.
All obese participants had BMI score above 33.38 of T2DM and
36 of atherosclerosis patients also had BMI above 30. Previous
myocardial infarction was also noted for 18 diabetes subjects,
whereas 2 atherosclerosis patients were also diagnosed with
diabetes.
Proven Pathogenic Mutations
We examined disease patients and control individuals for
the presence of proven pathogenic variants in mtDNA.
None of the subjects had the m.3243A>G mutation which
has been associated with the MIDD syndrome. We found
in total 2 individuals (1 obese and 1 with atherosclerosis)
with the m.1555A>G mutation at a heteroplasmic (11.81%)
and homoplasmic level, respectively, that is associated with
aminoglycoside-induced and non-syndromic sensorineural
deafness transmitted in a maternal manner.
Mitochondrial Haplogroup Distribution
In total, 15 different mitochondrial haplogroups were
identified in the studied cohorts, their observed frequencies
are summarized in Table 2. No statistically significant differences
were noted in T2DM (Fisher’s exact test value 13.213, p =
0.319), obesity (16.736, p = 0.154) or atherosclerosis (18.203,
p = 0.128) when compared for total haplogroup composition
with the common control group. However, post-hoc analysis of
the contingency table using the adjusted standardized residual
method indicated lower than expected prevalence of haplogroup
V in T2DM patients when compared to the control group (1 vs.
7%, adj. std. res.−2.18, p= 0.02961, φ=−0.148). Moreover, the
test residuals revealed also that fewer obese and atherosclerotic
subjects were assigned to haplogroup U when compared to
controls (12 vs. 26 %, adj. std. res. −2.60, p = 0.00936, φ =
−0.177 for obesity; 15 vs. 26 %, adj. std. res. −1.99, p = 0.04624,
φ = −0.136 for atherosclerosis). None of the post-hoc analysis
p-values was, however, significant after Bonferroni correction for
multiple testing.
Rare mtDNA Variants
We identified in total 498, 506, 531, and 543 non-synonymous
mtDNA variants in patients with T2DM, obesity, atherosclerosis
and control individuals, respectively. We specified variants
present exclusively in each of the studied groups (unique
variants) in order to have a clear distinction between groups
and increase possible signal. Variant population frequency was
determined based on the prevalence in mtDNA sequences in the
GenBank database. To test if frequency of rare non-synonymous
variants differs between each of the disease cohorts and control
subjects, and in particular if rare variants are overrepresented in
any of the studied phenotypes, we compared the numbers of rare
(<0.1%) and common (>1%) non-synonymous variants. We did
not find any differences between any of the disease cohorts and
controls, as shown in Table 3.
MutPred Variant Load
Total variant loads using variants with MutPred scores above
>0.5 were calculated for each participant in the studied cohorts
and are presented in Figure 1. For the exact variant load
values with the number of non-synonymous substitutions see
the Supplemental Tables 2–5. To test whether higher MutPred
derived mildly deleterious variant load might be an indication
of a complex trait we compared total loads between all groups
using one-way ANOVA. Although all three disease groups had
higher mean variant load levels than controls (means with SD
for T2DM, obesity, atherosclerosis and control cohorts were 0.58
± 0.61, 0.63 ± 0.66, 0.70 ± 0.70, and 0.48 ± 0.58, respectively),
no significant differences were observed (p = 0.096). However,
Dunnett’s two-tailed post-hoc test used to compare each disease
phenotype to the single common control group indicated
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TABLE 1 | Characteristics of the complex trait patients and the control group.
Parameter T2DM Obesity Atherosclerosis Controls
Number of participants (n) 100 100 100 115
Women 50 50 50 59
Men 50 50 50 56
Mean age ± SD (year) 59.3 ± 10.10 54.7 ± 9.26 55.5 ± 7.30 56.7 ± 9.49
BMI ± SD 29.7 ± 6.58a 38.5 ± 5.22 29.1 ± 5.20 22.7 ± 1.81
Fasting glucose levels ± SD (mmol/l) n/a 5.8 ± 2.01b 5.4 ± 0.88c 4.8 ± 0.40
aFor 3 T2DM patients BMI data were unavailable.
bFor 2 obese patients fasting glucose data were unavailable.
cFor 1 atherosclerosis patient fasting glucose data were unavailable.
TABLE 2 | Prevalence of mitochondrial haplogroups in the studied cohorts.
Mitochondrial DNA haplogroup T2DM patients (n = 100) Obesity patients (n = 100) Atherosclerosis patients (n = 100) Control subjects (n = 115)
C 1 0 1 1
D 0 1 0 2
G 0 0 1 0
H 42 37 40 43
HV 0 1 1 2
I 5 2 3 1
J 9 13 10 7
K 4 6 3 6
N 0 2 2 0
R 1 0 0 2
T 10 14 14 8
U 22 12 15 30
V 1 6 3 8
W 3 3 6 3
X 2 3 1 2
TABLE 3 | Number of rare (<0.1%) and common (>1%) non-synonymous
variants unique to T2DM, obesity, atherosclerosis, and the control group.
GenBank frequency Disease group Control group P-value
T2DM
<0.1% 22 27 1
>1% 3 5
OBESITY
<0.1% 14 28 1
>1% 4 9
ATHEROSCLEROSIS
<0.1% 26 28 0.675
>1% 2 4
P-value from Fisher’s exact test.
significantly higher variant load in atherosclerosis patients (p =
0.041). None of the remaining groups was found to be different
from controls.
Next, we tested if disease cohorts differ in the number
of variants with high (>0.5) and very high (>0.7) MutPred
scores when compared to controls. The number of subjects
within the studied groups carrying mtDNA variants above 0.5
or 0.7 MutPred threshold is listed in Table 4. We observed
that atherosclerosis patients were more likely to have high
pathogenicity scored variants when compared to controls (65% of
atherosclerosis group and 50% of controls, p = 0.038). However,
the difference was not robust enough to withstand correction for
multiple comparisons and, moreover, the significance was lost
when the 0.7 MutPred threshold was applied (Table 4). This can
be attributed to the small number of individuals having variants
with MutPred scores >0.7. None of the remaining groups was
found to be different from controls.We also investigated if having
more than one variant with high MutPred score (>0.5) might be
associated with disease development. The number of individuals
in each disease phenotype was compared to controls by frequency
of variants that is having 0, 1, or 2+ non-synonymous sequence
changes with above 0.5 pathogenic score. As shown in Table 5,
none of the disease groups were observed to differ significantly
from controls in variant number distribution.
Observing that there is a tendency for having multiple
rather than single mtDNA variants with MutPred score above
0.5 in disease cohorts when compared to the control group,
we investigated the variants in more detail. Interestingly, we
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FIGURE 1 | Total variant loads based on only non-synonymous variants with
MutPred score above 0.5 threshold in T2DM (n = 100), obesity (n = 100),
atherosclerosis (n = 100) and the control group (n = 115). No significant
differences were observed when comparing all groups with one-way ANOVA
(p = 0.096). Dunnett’s post-hoc test revealed a significant difference between
the atherosclerosis cohort and the control group (p = 0.041) in mean total
variant load.
TABLE 4 | Frequency of complex trait and control subjects having high scoring
(>0.5 or >0.7) mtDNA variants with MutPred analysis.
MutPred threshold Disease group Control group P-value
T2DM
>0.5 59 58 0.220
≤0.5 41 57
>0.7 8 11 0.811
≤0.7 92 104
OBESITY
>0.5 58 58 0.276
≤0.5 42 57
>0.7 8 11 0.811
≤0.7 92 104
ATHEROSCLEROSIS
>0.5 65 58 0.038
≤0.5 35 57
>0.7 10 11 1
≤0.7 90 104
P-value from Fisher’s exact test.
noted that several common population variants associated
with different mtDNA haplogroups were still present in our
subjects even with the high MutPred score threshold (Table 6).
Common population mtDNA variants that are associated with
haplogroups, besides rare variants, have been observed to have
high MutPred scores also by other authors, e.g., Venter et al.
(2017). However, significance of such variation has been debated
and whether they exert a phenotypic effect may be dependent
on genetic background, e.g. haplogroup context (Queen et al.,
TABLE 5 | Number of subjects having one or more high scoring (>0.5) mtDNA
variants with MutPred analysis.
Number of variants with
MutPred score >0.5
Number of
disease subjects
Number of control
individuals
P-value
T2DM
0 41 57 0.434
1 30 31
2+ 29 27
OBESITY
0 42 57 0.134
1 22 31
2+ 36 27
ATHEROSCLEROSIS
0 35 57 0.083
1 31 31
2+ 34 27
P-value from Fisher’s exact test.
2017; O’Keefe et al., 2018). Additionally, the majority of subjects
having 2 or more variants with MutPred score above 0.5, had a
combination of relatively common variants only, as presented
in Figure 2. Those with atherosclerosis were noted to have the
highest number of subjects with a combination of a common and
a rare (not frequently associated with a particular haplogroup)
variants in comparison to other cohorts (Figure 2).
DISCUSSION
Mitochondrial dysfunction and inherited mtDNA variation
have been implicated in the development of common complex
cardiovascular and metabolic diseases (Wallace, 2013; Venter
et al., 2018). In this study we investigated mtDNA variation
in Polish subjects with obesity, diabetes and atherosclerosis to
test whether it might have an impact on disease susceptibility
in this population. Screening for the presence of proven
pathogenic variants in mtDNA revealed only one change,
m.1555A>G, which is associated with deafness, present in
two subjects. The m.1555A>G mutation was reported at the
frequency of 0.4% in the general Polish population (Rydzanicz
et al., 2009). Considering the similar prevalence of m.1555A>G
variant in our study (0.48%, 2/415) and the known reduced
penetrance of hearing loss in individuals who are not exposed to
aminoglycoside antibiotics (Usami and Nishio, 1993), we think
this finding is incidental.
Many studies have reported mitochondrial haplogroup
associations with complex traits, but a number of problems
with this model have been shown (Salas and Elson, 2015).
A single haplogroup-associated common variant might have
occurred more than once in different branches of the mtDNA
phylogeny, which complicates haplogroup association studies
(Herrnstadt et al., 2002). Moreover, such analysis investigates
common polymorphic variation rather than rare variants,
which are most likely to be mildly deleterious. Complications
in haplogroup studies are also caused by a high level of
Frontiers in Genetics | www.frontiersin.org 6 January 2019 | Volume 9 | Article 702
Piotrowska-Nowak et al. Mildly Deleterious mtDNA Variants in Atherosclerosis
TABLE 6 | Common variants with MutPred score above 0.5 and associated with mtDNA haplogroups found in disease cohorts and the control group.
Mitochondrial
variant
MutPred
score
GenBank
frequency
Number of T2DM
sequences
Number of
obesity
sequences
Number of
atherosclerosis
sequences
Number of
control
sequences
Associated
haplogroupsa
Comment
m.3394T>C 0.783 1.36% 1 4 0 0 8 haplogroup
associated
m.4216T>C 0.611 10.01% 20 27 24 18 14 haplogroup
definingb
m.4917A>G 0.628 4.75% 10 14 14 8 5 haplogroup
definingb
m.5460G>A 0.505 6.23% 6 7 10 8 36 haplogroup
associated
m.8414C>T 0.513 4.01% 0 1 0 2 1 haplogroup
associated
m.8584G>A 0.553 5.01% 1 0 1 1 5 haplogroup
associated
m.11969G>A 0.639 1.34% 0 0 1 1 5 haplogroup
associated
m.12811T>C 0.587 1.08% 1 0 1 0 3 haplogroup
associated
m.13780A>G 0.606 1.76% 5 4 4 1 1 haplogroup
associated
m.14798T>C 0.609 6.76% 12 17 10 11 5 haplogroup
associated
m.15204T>C 0.547 1.25% 0 0 0 1 4 haplogroup
associated
m.15257G>A 0.785 1.61% 1 1 2 2 3 haplogroup
associated
m.15812G>A 0.518 1.02% 0 0 1 0 3 haplogroup
associated
aNumber of hits in Phylotree.
bBased on haplogroup markers from Mitomap database.
FIGURE 2 | Frequency of subjects having two or more mtDNA variants with
MutPred score above 0.5 in disease cohorts and the control group. The
majority of individuals had a combination of two or more common variants only.
population stratification when considering mtDNA variation,
due to mtDNA’s small effective population size (Salas and Elson,
2015; Pienaar et al., 2017). As a result, many studies fail to
replicate findings from similar prior studies (Chinnery et al.,
2007; Knoll et al., 2014), resulting in a myriad of conflicts in the
literature. Having this in mind, we investigated the distribution
of mitochondrial haplogroups in our cohorts and found that
mitochondrial haplogroup V was underrepresented in T2DM,
whereas haplogroup U was underrepresented in obesity and
atherosclerosis. The significances of these associations were,
however, not robust enough to withstand correction for multiple
comparisons, thus a protective role of two mtDNA haplogroups
in the development of the studied complex traits could not be
confirmed.
We then tested if rare (GenBank frequency below 0.1%)
non-synonymous substitutions were more common in cases
than controls, we found no significant differences across
studied groups. However, this negative result is based solely
on population frequency data, and not all variants will be
mildly deleterious, some will one day become common. Thus,
we adopted a mutational or variant load model and used
the MutPred tool to predict the impact of non-synonymous
substitutions, to ensure the best possible predictive model was
applied.
The MutPred variant load method presented here focuses on
population variants with a score above 0.5 that are predicted to
be mildly deleterious to protein function, and thus tend to be
rare variants being found at the tips of the phylogeny. These
rare variants are less likely to be impacted on by population
stratification (Elson et al., 2004; Pereira et al., 2011; Venter et al.,
Frontiers in Genetics | www.frontiersin.org 7 January 2019 | Volume 9 | Article 702
Piotrowska-Nowak et al. Mildly Deleterious mtDNA Variants in Atherosclerosis
2017), with population stratification thought to be a cause of
false associations in prior haplogroup based association studies.
By using only mtDNA variants with a MutPred score above
0.5, the effect of the reference sequence on the phylogeny is
also largely mitigated, as reported in the paper of Venter et al.
(2017), which showed the number of variants in sequences
of African and European background were similar under this
condition. Additionally, low scoring variants are more common,
and of questionable impact thus excluding them from the analysis
aims also at reducing likely background noise in the analysis.
Using this method, we noted a borderline significant difference
in atherosclerosis patients that had higher MutPred derived
mildly deleterious variant loads. Moreover, they were more
likely to have at least one high (>0.5) pathogenicity scored
non-synonymous substitution than controls (Table 4), yet the
statistical significance of this finding was not robust enough
to withstand correction for multiple testing. Overall, we have
not observed affected individuals to be more likely to have
multiple high scoring non-synonymous variants, however, there
was a marginally significant result in the atherosclerosis group
(Table 5). Combined with the ANOVA analysis, our results
suggest that if mtDNA variation is involved in atherosclerosis
development, individuals are likely to require more than one
mildly deleterious variant to be more susceptible to the disease.
Investigating larger cohorts would be better powered to detect
such synergistic effect as individuals with two or more such
variants only represent around 30% of the population.
It is important to mention that not all of the variants with
MutPred scores >0.5 are rare, we observed some common
population mtDNA polymorphisms to have a high MutPred
score (above 0.5, Table 6). Moreover, we noted that very few
subjects have two or more rare high scoring variants. Thus, we
hypothesize that rare mtDNA variants acting in synergy within
individuals having any of the studied phenotypes is an unlikely
to be a common element in their etiology. Rather, the presence
of multiple high scoring common haplogroup associated variants
was the most prevalent configuration where two variants of
predicted mildly deleterious effect were seen. In the context of
interpreting these results it is worth considering the evidence
that mitochondrial haplogroup context may influence the impact
or penetrance of clinically proven mtDNA mutations (Chinnery
et al., 1999; Hudson et al., 2007; Queen et al., 2017; Wei et al.,
2017), as such it might be possible that the impact of more
common variants is also dependent on haplogroup background
making these observations complex to interpret. That is a high
scoring common variant might have been miss-assigned the high
value by the MutPred algorithm, or it might be appropriately
scored but the deleterious effect might be masked by other
variants on the lineage where it is commonly found.
Interestingly, atherosclerosis subjects had the highest
tendency to have at least one common haplogroup associated
variant and a rare variant with a MutPred score >0.5 when
compared to other groups. This lends some supports to a two-hit
hypothesis (Knudson, 1971) that is when acquiring another
mildly deleterious variant if already having a high scoring
common haplogroup variant might result in some subtle change
to risk of atherosclerosis. One of the strengths of the MutPred
load measure being that it is able to detect the synergistic effect
between high-scoring common variants and rare variants, and
such an interaction might have resulted in the borderline effect
observed in this study.
In summary, we present an advance on the mutational or
variant load hypothesis for the study of the role of mtDNA
variation in common complex traits. Although the MutPred
load method is designed to be less vulnerable to the effects
of population stratification, we showed in our study that this
measure is not completely independent of haplogroup context
as it will lead to the inclusion of some common haplogroup
associated variants. Moreover, we present a possible association
between mildly deleterious mtDNA variants and atherosclerosis
that might be due to a subset of individuals having more
than one likely mildly deleterious variant and that seems
largely dependent upon a few common haplogroup variants
with MutPred score above 0.5. Particular emphasis is laid on
the possibility of a synergistic effect or interplay of common
mtDNA haplogroup associated variants with MutPred scores
>0.5 in combination with rarer variants of similar MutPred
score in disease susceptibility. These mildly deleterious non-
synonymousmtDNA variants, especially acting in synergy, might
influence the function of the respiratory chain. A possible
mild change in the function of subunits of its complexes
may in consequence lead to the increase in ROS production
that would, together with other risk factors, contribute to the
disease development. For full discussion on the putative role
of mitochondria and mtDNA in the etiology of cardiovascular
diseases we recommend a paper by Venter et al. (2018) and Yu
et al. (2012).
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